First and Only Ready-to-Dilute, Multi-Dose Vial of Thiotepa Approved

The FDA approved the 100 mg/10 mL multi-dose vial of Tepylute, a ready-to-dilute formulation of thiotepa to treat breast and ovarian cancers, that eliminates the need for reconstitution and may reduce preparation time and errors, thus offering more scheduling flexibility for patients.